Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 211280

Expand all

REYVOW (LASMIDITAN SUCCINATE)
EQ 50MG BASE
Marketing Status: Prescription

Active Ingredient: LASMIDITAN SUCCINATE
Proprietary Name: REYVOW
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 50MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N211280
Product Number: 001
Approval Date: Jan 31, 2020
Applicant Holder Full Name: ELI LILLY AND CO
Marketing Status:  Prescription
Patent and Exclusivity Information

REYVOW (LASMIDITAN SUCCINATE)
EQ 100MG BASE
Marketing Status: Prescription

Active Ingredient: LASMIDITAN SUCCINATE
Proprietary Name: REYVOW
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 100MG BASE
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N211280
Product Number: 002
Approval Date: Jan 31, 2020
Applicant Holder Full Name: ELI LILLY AND CO
Marketing Status:  Prescription
Patent and Exclusivity Information

REYVOW (LASMIDITAN SUCCINATE)
EQ 200MG BASE
Marketing Status: Discontinued

Active Ingredient: LASMIDITAN SUCCINATE
Proprietary Name: REYVOW
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 200MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N211280
Product Number: 003
Approval Date: Dec 18, 2020
Applicant Holder Full Name: ELI LILLY AND CO
Marketing Status:  Discontinued
Patent and Exclusivity Information